NASDAQ:OMER - Omeros Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$17.58 +0.02 (+0.11 %)
(As of 03/20/2019 01:36 PM ET)
Previous Close$17.56
Today's Range$17.25 - $17.86
52-Week Range$10.30 - $27.00
Volume17,483 shs
Average Volume887,105 shs
Market Capitalization$861.60 million
P/E Ratio-7.93
Dividend YieldN/A
Beta3.58
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. Its clinical programs include OMS721 that is in Phase III clinical trial for treating immunoglobulin A (IgA) nephropathy, hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA), and atypical hemolytic uremic syndrome (aHUS); and in Phase II clinical trial to treat IgA nephropathy, membranous nephropathy, lupus nephritis, and complement component glomerulopathy. The company's clinical programs also consists of OMS824, which is in Phase II clinical trial for treating Huntington's diseases and schizophrenia; and OMS405 that is in Phase II clinical trial to treat opioids, nicotine, and alcohol addiction. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; and OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. The company's preclinical programs also include MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HCT-TMA, and age-related macular degeneration; MASP-3-small-molecule inhibitors used for the treatment of PNH and other alternative pathway disorders; G protein-coupled receptor (GPCR) platform, including GPR174 and other Class A orphan GPCRS for treating CNS, metabolic, CV, oncologic, musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal and other disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

Receive OMER News and Ratings via Email

Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:OMER
CUSIP68214310
Phone206-676-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.87 million
Book Value($2.04) per share

Profitability

Net Income$-126,760,000.00
Net Margins-424.39%

Miscellaneous

EmployeesN/A
Market Cap$861.60 million
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable

Omeros (NASDAQ:OMER) Frequently Asked Questions

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) posted its earnings results on Friday, March, 1st. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.75) by $0.27. The biopharmaceutical company earned $22.02 million during the quarter, compared to the consensus estimate of $22.42 million. The firm's revenue for the quarter was up 60.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.34) EPS. View Omeros' Earnings History.

When is Omeros' next earnings date?

Omeros is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Omeros.

What price target have analysts set for OMER?

5 analysts have issued 1-year price targets for Omeros' stock. Their forecasts range from $20.00 to $75.00. On average, they expect Omeros' share price to reach $38.40 in the next year. This suggests a possible upside of 118.4% from the stock's current price. View Analyst Price Targets for Omeros.

What is the consensus analysts' recommendation for Omeros?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omeros.

What are Wall Street analysts saying about Omeros stock?

Here are some recent quotes from research analysts about Omeros stock:
  • 1. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (3/7/2019)
  • 2. HC Wainwright analysts commented, "We note that the performance vs. consensus was substantially more impressive, as Omeros delivered top-line results that were $6M ahead of consensus estimates and bottom-line numbers that were $0.26 better than consensus. Management indicated on its earnings conference call the strong year-end performance of OMIDRIA, which is currently covered for nearly 90% of relevant lives and which is on a $100M annualized revenue run rate as of December 2018. Investors should note that we expect OMIDRIA revenue to meaningfully accelerate over the course of this year and well into 2020, with our full-year 2019 revenue projection currently at $165.4M and 2020 top-line revenue estimated at $242.3M. Given the strength of the OMIDRIA franchise and the potential for multiple near-term pipeline catalysts, notably the start of a possible regulatory filing in the U.S." (3/4/2019)
  • 3. Maxim Group analysts commented, "Omeros reported 3Q18 with $4.6M in Omidria revenues, up from $1.7M in 2Q18. Omeros reported a net loss for the quarter of ($39.5M), and a cash balance of $55M, excluding the $210M debt offering announced concurrently. OMER shares are down ~20%, in our view, due to a misunderstanding of the financing." (11/9/2018)

Has Omeros been receiving favorable news coverage?

Headlines about OMER stock have trended somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Omeros earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.

Who are some of Omeros' key competitors?

What other stocks do shareholders of Omeros own?

Who are Omeros' key executives?

Omeros' management team includes the folowing people:
  • Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 60)
  • Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 61)
  • Ms. Marcia S. Kelbon, VP of Patent, Gen. Counsel & Sec. (Age 59)
  • Dr. Pamela Pierce Palmer, Co-Founder (Age 56)
  • Dr. George A. Gaitanaris, Chief Scientific Officer & VP of Science (Age 62)

Who are Omeros' major shareholders?

Omeros' stock is owned by many different of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (10.55%), BlackRock Inc. (8.14%), D. E. Shaw & Co. Inc. (3.90%), Millennium Management LLC (2.27%), Cpwm LLC (1.48%) and Northern Trust Corp (1.26%). Company insiders that own Omeros stock include Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros.

Which institutional investors are selling Omeros stock?

OMER stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Cpwm LLC, Nisa Investment Advisors LLC, Raymond James & Associates, Stifel Financial Corp, MetLife Investment Advisors LLC, Northern Trust Corp and New York State Common Retirement Fund. Company insiders that have sold Omeros company stock in the last year include Marcia S Kelbon and Michael A Jacobsen. View Insider Buying and Selling for Omeros.

Which institutional investors are buying Omeros stock?

OMER stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, D. E. Shaw & Co. Inc., SG Americas Securities LLC, First Trust Advisors LP, Capital Impact Advisors LLC, Geode Capital Management LLC, Geode Capital Management LLC and BlackRock Inc.. View Insider Buying and Selling for Omeros.

How do I buy shares of Omeros?

Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $17.58.

How big of a company is Omeros?

Omeros has a market capitalization of $861.60 million and generates $29.87 million in revenue each year. The biopharmaceutical company earns $-126,760,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis.

What is Omeros' official website?

The official website for Omeros is http://www.omeros.com.

How can I contact Omeros?

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.


MarketBeat Community Rating for Omeros (NASDAQ OMER)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  566 (Vote Outperform)
Underperform Votes:  338 (Vote Underperform)
Total Votes:  904
MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote "Outperform" if you believe OMER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/20/2019 by MarketBeat.com Staff

Featured Article: What is a capital gain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel